Cancer Biologics Market Size to Rise USD 214.59 Bn by 2033

The global cancer biologics market size is anticipated to grow around USD 214.59 billion by 2033, growing at a CAGR of 7.12% from 2024 to 2033.

Key Points

  • North America dominated the cancer biologics market in 2023
  • Asia Pacific is expected to grow steadily in the market during the forecast period.
  • The monoclonal antibodies segment dominated the market by drug class in 2023.
  • The cancer growth inhibitors segment is expected to grow to the highest CAGR in the market by application during the forecast period.
  • The blood cancer segment dominated the market by application in 2023.
  • The lung cancer segment is expected to grow to the highest CAGR in the market by application during the forecast period.
  • In 2023, the hospital segment dominated the market by end-use.
  • The cancer center segment is expected to grow to the highest CAGR in the market by end-use during the forecast period.

Cancer Biologics Market Size 2024 to 2033

The global cancer biologics market has witnessed significant growth over the past decade, driven by increasing prevalence of cancer worldwide and advancements in biotechnology and oncology research. Cancer biologics refer to therapeutic agents derived from living organisms or their components, including monoclonal antibodies, cytokines, cancer vaccines, and targeted therapies. These biologics have revolutionized cancer treatment by offering more precise and effective therapeutic options compared to traditional chemotherapy.

Get a Sample:

One of the key growth factors contributing to the expansion of the cancer biologics market is the rising incidence of cancer globally. According to the World Health Organization (WHO), cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 10 million cancer-related deaths reported annually. As the burden of cancer continues to increase, there is a growing demand for innovative treatment modalities, including biologics, to address the diverse needs of cancer patients.

Regionally, North America dominates the cancer biologics market, accounting for a significant share of the global revenue. The presence of well-established healthcare infrastructure, favorable reimbursement policies, and robust research and development activities in the region contribute to its leadership position. Additionally, the Asia-Pacific region is witnessing rapid growth in the cancer biologics market, fueled by increasing investments in healthcare infrastructure, rising disposable income, and growing awareness about advanced cancer therapies.

Cancer Biologics Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 7.12%
Global Market Size in 2023 USD 102.01 Billion
Global Market Size by 2033 USD 214.59 Billion
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Drug Class, By Applications, and By End-use
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Cancer Biologics Market Dynamics

Several drivers are propelling the growth of the cancer biologics market. These include the expanding pipeline of novel biologics targeting various types of cancer, advancements in biotechnology leading to the development of more potent and targeted therapies, and the increasing adoption of personalized medicine approaches in cancer treatment. Moreover, collaborations and strategic partnerships between pharmaceutical companies and research institutions are driving innovation and accelerating the development of new cancer biologics.

The cancer biologics market presents numerous opportunities for growth and expansion. With ongoing research and development efforts focused on identifying new therapeutic targets and enhancing the efficacy of existing biologics, there is a vast potential for the introduction of novel cancer treatments. Additionally, the growing trend towards precision medicine and molecular diagnostics is expected to create opportunities for the development of personalized biologics tailored to individual patient profiles.

Despite the promising outlook, the cancer biologics market also faces several challenges. High development costs, stringent regulatory requirements, and complex manufacturing processes pose significant barriers to entry for smaller biotechnology companies. Moreover, the emergence of biosimilars and the potential for intellectual property disputes could impact the market dynamics and competition among biologics manufacturers. Additionally, access to cancer biologics remains a challenge in many low- and middle-income countries, highlighting the need for greater investment in healthcare infrastructure and affordability initiatives.

Read Also: Medical Device Connectivity Market Size, Trends, Report by 2033

Recent Developments

  • Dr. Reddy’s Laboratories declared in March 2024 that Versavo® (bevacizumab) would be available in the UK. Avastin’s biosimilar Versavo is effective against multiple cancer types, such as advanced non-squamous non-small cell lung cancer, metastatic colorectal cancer, ovarian cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and metastatic breast cancer.
  • BioNTech and Duality Biologics declared in January 2024 that a Phase III trial of a medication for breast cancer has begun. BioNTech and Duality are conducting a Phase III trial to evaluate their antibody-drug conjugate in patients whose tumors have low levels of progesterone or estrogen and respond to these hormones. This corresponds to between 40% and 45% of patients with metastatic breast cancer who are on Herceptin for HER2.
  • Angle, a liquid biopsy firm that provides diagnostic solutions for circulating tumor cells (CTCs) in drug development, research, and clinical oncology, announced in November 2023 that the Portrait PD-L1 test would be available for CTCs to assess PD-L1 protein expression.
  • In April 2023, TORL BioTherapeutics LLC, a biopharmaceutical company focused on developing new biologics for cancer treatment, announced its public launch and the closing of a $158 million Series B financing.

Cancer Biologics Market Companies

  • Abbott
  • Angel
  • Amgen, Inc
  • AstraZeneca
  • BioNTech
  • Bristol-Mayer Squibb Company
  • Dr. Reddy’s Laboratories
  • Duality Biologics
  • Eli Lilly and Company
  • F.Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals Ltd
  • GSK plc.
  • Ichnos Sciences Inc
  • Johnson & Johnson Services, Inc
  • Pfizer, Inc
  • TFC Therapeutics

Segments Covered in the Report

By Drug Class

  • Monoclonal Antibodies
    • Naked Monoclonal Antibodies
    • Conjugated Monoclonal Antibodies
    • Bispecific Monoclonal Antibodies
  • Cancer Growth Inhibitors
    • Tyrosine Kinase Inhibitor
    • Mtor Inhibitors
    • Proteasome Inhibitors
    • Others
  • Vaccines
    • Preventive Vaccines
    • Therapeutic Vaccines
  • Recombinants Proteins
  • CAR-T Cells
  • Angiogenesis Inhibitors
  • Interleukins (IL)
  • Interferons (IFN)
  • Gene Therapy
  • Others

By Applications

  • Blood Cancer
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Gastric Cancer
  • Ovarian Cancer
  • Skin Cancer
  • Liver Cancer
  • Others

By End use

  • Hospitals
  • Cancer Center
  • Academics & Research Institutes

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333









I have completed my education in Bachelors in Computer Application. A focused learner having a keen interest in the field of digital marketing, SEO, SMM, and Google Analytics enthusiastic to learn new things along with building leadership skills.


I have completed my education in Bachelors in Computer Application. A focused learner having a keen interest in the field of digital marketing, SEO, SMM, and Google Analytics enthusiastic to learn new things along with building leadership skills.

View all posts by Prathamesh →

Leave a Reply

Your email address will not be published. Required fields are marked *